21April

Novo Nordisk A/S - Reduction of the share capital ... Read more

03April

Once-weekly semaglutide demonstrated consistent blood glucose reductions and wei ... Read more

24April

Novo Nordisk A/S - Share repurchase programme ... Read more

21April

Novo Nordisk A/S - Reduction of the share capital ... Read more

10April

Novo Nordisk A/S - Share repurchase programme ... Read more

03April

Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations

 

Novo Nordisk News


Global research, haemophilia

Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B

24 March - The CHMP under the European Medicines Agency have adopted a positive opinion for the use of Refixia® (nonacog beta pegol, N9-GP), recommending marketing authorisation for the treatment of adolescents and adults with haemophilia B. The CHMP recommends Refixia®, the brand name for N9-GP, to be indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescent (≥12 years of age) and adult patients with haemophilia B. “We are excited about the positive opinion obtained for Refixia® and it represents a significant milestone in our efforts to expand the treatment options for patients with haemophilia,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “We believe Refixia® with its strong clinical profile provides haemophilia B patients better protection against bleeds, even into damaged joints, and an overall improved quality of life.”  

Read the entire company announcement

 


Tresiba; device manufacturing

CHMP provides positive opinion for EU label update for Novo Nordisk’s Tresiba® based on data from SWITCH trials 

24 March - The CHMP, under the European Medicines Agency, has issued a positive opinion, recommending an update of the label for Tresiba® (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials. In the trials, Tresiba®, the new-generation once-daily basal insulin, demonstrated clinically relevant reductions in hypoglycaemia compared with insulin glargine U100 in people with type 1 and type 2 diabetes.

“Following the submission of the application to the EMA in November 2016, we are very pleased to have received a positive opinion from the CHMP for the label update already at this point in time,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. “An inclusion of the SWITCH trial results in the label will further support the clinical profile of Tresiba®”.

Read the full announcement

 



The Novo Nordisk Research Centre Oxford

Novo Nordisk and University of Oxford entering collaboration on type 2 diabetes with GBP 115m investment

30 January - University of Oxford and Novo Nordisk has announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. Sir John Bell, Regius Professor of Medicine, University of Oxford, said: “We see the collaboration with Novo Nordisk as an outstanding opportunity to mix competence embedded at our campus with Novo Nordisk’s groundbreaking research and results in diabetes. This collaboration underlines the importance of shared research and cutting-edge science across boundaries". The Novo Nordisk Research Centre Oxford will employ up to 100 Novo Nordisk researchers.

Read the press release

 


Novo Nordisk and Glooko partner to develop digital health solutions 

Novo Nordisk and Glooko will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. Read all the details


The hidden talents

Imagine that you perceive the noise level in the canteen as 100 times louder, and that even minor changes in your daily life cause you to lose your overview. Such is life for 28-year-old Louise Wille, who has Asperger’s and ADHD.

Read the whole story

Louise Wille

Going 100% renewable

Our production site in Tianjin rose to the challenge of moving away from coal-based energy and reached its goal of using 100% renewable power for all its production - made possible through the purchase of green energy from a wind farm in Leo’s hometown.

Read the story from Leo's perspective

Going 100% renewable in China

Sarah Ahmed from Ethopia has type 1 diabetes

Novo Nordisk committed to guarantee access to insulin

22 September - Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.

Read all the details about Novo Nordisk's programme on access to insulin

The diabetes challenge - get an overview of Novo Nordisk's commitment 


Calendar

Q3 financial results
03MayWorldwide

Annual report 2016

Read about former CEO Lars Rebien Sørensen's reflections on 2016 and present CEO Lars Fruergaard Jørgensen's thoughts about the road ahead for Novo Nordisk and much more in the Annual Report 2016


Dealing with dilemmas

Read about: Risky business! - What are the most pressing dilemmas businesses will face in 2017? - Navigating in the eye of the storm and - How long is long-term commitment? - and much more


An exceptional patient entrepreneur!

Winner of Lyfebulb award

Dec '16 - Patient entrepreneur Brianna Wolin was selected as winner of the Lyfebulb-Novo Nordisk Innovation Award: 'Find Your Ditto' - a mobile platform which connects patients living with the same chronic illness for on-demand, in-person peer support.

Read more about the Lyfebulb-Novo Nordisk partnership


Novo Nordisk in brief


Get an instant impression of what Novo Nordisk is about, see the numbers and read about partnership activities that drive change. 

Download Novo Nordisk backgrounder 


Novo Nordisk Stories

Views on obesity

The view on obesity is slowly changing, but there are still many myths about the disease that all contribute to creating barriers for proper treatment.

Read the story

Theme: Innovation